Evidence map›Paper›PMID 32407491›Full record

ArticleBioinformatics (Oxford, England)2020

iBioProVis: interactive visualization and analysis of compound bioactivity space.

Ataberk Donmez, Ahmet Sureyya Rifaioglu, Aybar Acar, Tunca Doğan, Rengul Cetin-Atalay, Volkan Atalay

Erratum issuedAbstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Applying the digital data and the bioinformatics tools in SARS-CoV-2 research.Computational and structural biotechnology journal · 2023
    Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Ataberk DonmezDepartment of Computer Engineering, METU, Ankara 06800, Turkey.
Ahmet Sureyya RifaiogluDepartment of Computer Engineering, METU, Ankara 06800, Turkey.
Aybar AcarDepartment of Health Informatics, KanSiL, Graduate School of Informatics, METU.
Tunca DoğanDepartment of Computer Engineering, Hacettepe University, 06800 Ankara, Turkey.
Rengul Cetin-AtalayDepartment of Health Informatics, KanSiL, Graduate School of Informatics, METU.
Volkan AtalayDepartment of Computer Engineering, METU, Ankara 06800, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

summaryiBioProVis is an interactive tool for visual analysis of the compound bioactivity space in the context of target proteins, drugs and drug candidate compounds. iBioProVis tool takes target protein identifiers and, optionally, compound SMILES as input, and uses the state-of-the-art non-linear dimensionality reduction method t-Distributed Stochastic Neighbor Embedding (t-SNE) to plot the distribution of compounds embedded in a 2D map, based on the similarity of structural properties of compounds and in the context of compounds' cognate targets. Similar compounds, which are embedded to proximate points on the 2D map, may bind the same or similar target proteins. Thus, iBioProVis can be used to easily observe the structural distribution of one or two target proteins' known ligands on the 2D compound space, and to infer new binders to the same protein, or to infer new potential target(s) for a compound of interest, based on this distribution. Principal component analysis (PCA) projection of the input compounds is also provided, Hence the user can interactively observe the same compound or a group of selected compounds which is projected by both PCA and embedded by t-SNE. iBioProVis also provides detailed information about drugs and drug candidate compounds through cross-references to widely used and well-known databases, in the form of linked table views. Two use-case studies were demonstrated, one being on angiotensin-converting enzyme 2 (ACE2) protein which is Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike protein receptor. ACE2 binding compounds and seven antiviral drugs were closely embedded in which two of them have been under clinical trial for Coronavirus disease 19 (COVID-19). AVAILABILITY AND IMPLEMENTATION: iBioProVis and its carefully filtered dataset are available at https://ibpv.kansil.org/ for public use. CONTACT: vatalay@metu.edu.tr. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

Indexed as

Models, MolecularSoftwareAngiotensin-Converting Enzyme 2Angiotensin-Converting Enzyme InhibitorsAntiviral AgentsBetacoronavirusCoronavirus InfectionsCOVID-19HumansInternetPandemicsPeptidyl-Dipeptidase APneumonia, ViralPrincipal Component AnalysisReceptors, Adrenergic, beta-2Receptors, Adrenergic, beta-3ACE2 protein, humanADRB2 protein, humanADRB3 protein, humanAngiotensin-Converting Enzyme 2Angiotensin-Converting Enzyme InhibitorsAntiviral AgentsPeptidyl-Dipeptidase AReceptors, Adrenergic, beta-2Receptors, Adrenergic, beta-3Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID32407491
PMCPMC7454317

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.